
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and adolescents between the ages of 12 and 17 years old. The bivalent version of its mRNA vaccine is designed to target both the original strain of SARS-CoV-2 and the BA.4/.5 omicron subvariants.